SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins better-than-expected quarterly results, stronger next-quarter outlook and expanded share-repurchase authorization sparked a sharp rebound. Bulls celebrated a potential recovery and short squeeze, while skeptics questioned whether growth deceleration and rising AI costs could limit the rally.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly results are drawing attention as weaker-than-expected daily-user growth and soft advertising trends weighed on the shares, despite a return to GAAP profitability and improved cash generation. Traders are split between concern that user and ad growth remain weak and optimism about profitability gains and the companys outlook.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp decline is being discussed as part of a broader semiconductor and AI-stock selloff, with traders speculating that election-related data-center restrictions or delays could weaken future AI infrastructure demand. Bulls call the move an overreaction given Microns strong results and memory demand, while bears point to cyclical supply risks and question whether the recent boom can last.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires Q3 results are driving attention, with a revenue shortfall weighing on shares while improved margins, record backlog and reaffirmed guidance fuel a more optimistic view. Traders are divided over whether the miss signals execution risk or reflects revenue timing while the business improves operationally.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzles strong quarterly results and another increase to its 2026 outlook, alongside an upbeat preliminary 2027 outlook, are driving attention. Bulls are celebrating the growth and speculating about short-covering, while some traders question whether projected growth is slowing enough to temper the rally.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys quarterly results beat expectations and its full-year revenue outlook was raised, alongside updates on FAA certification progress, aircraft production, and expanded Air Force work. Bulls welcomed the results and see momentum toward commercialization, while skeptics argue certification remains a lengthy process and question cash burn, dilution, and the air-taxi business model.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherents strong quarterly results and raised outlook, driven by AI data-center optical demand, are the main focus, but the shares are selling off despite the beat. Traders are split between viewing the pullback as broad AI-sector de-risking and worrying that data-center spending concerns could outweigh the companys growth outlook.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms quarterly results and outlook are driving attention: a modest earnings beat was overshadowed by falling handset sales and warnings that memory and supplier costs will pressure margins, contributing to a sharp after-hours selloff. Traders are split on whether growth in automotive, IoT and data-center chips can offset smartphone weakness.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff and lagging performance are being tied to trader concerns that the Democratic sweep could bring tighter AI and data-center rules, delaying infrastructure expansion and pressuring chip demand. Bulls argue the AI buildout will continue and view the decline as an overreaction, while others see regulatory and capex uncertainty as a risk to growth.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMAs reported Q3 earnings beat, strong ASCENIV growth and higher adjusted earnings outlook are driving attention, with traders celebrating the results and speculating that heavy short interest could fuel further gains. Some also point to sharp swings and profit-taking after the move, while the company reiterated its revenue guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire...

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?

Foghorn Therapeutics (FHTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR NewswireNEW YORK, Oct. 22, 2026 NEW YORK, Oct. 22, 2026 /PRNewswire...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026 /PRNewswire...

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (Foghorn or the Company) (NASDAQ: FHTX) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire...

FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%

Equity

Wedbush downgraded Foghorn to ‘Neutral’ from ‘Outperform,’ stating that its bullish thesis no longer applies after the partnership with Lilly ended.

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.read more...

FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?

Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.


Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Watertown, MA.

Foghorn Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>On Thursday, Foghorn said it would stop developing FHD-909, its experimental cancer drug, after its trial did not produce enough clinical efficacy.</li><li>Guggenheim kept a ‘Buy’ rating, saying Foghorn still has several potential opportunities in its wholly owned pipeline.</li><li>Foghorn cut about 40% of its workforce.</li></ul>Shares of Foghorn Therapeutics (FHTX) crashed more than 28% on Friday, adding to its 18% slump in the previous session, as Wall Street sounded caution after the biotech firm ended its cancer-drug collaboration with Eli Lilly (LLY).On Thursday, Foghorn said it would stop developing FHD-909, an experimental oral drug designed to block SMARCA2, a protein that certain cancers depend on to grow. The Phase 1 data showed the drug had a favorable safety profile but did not produce enough clinical efficacy to justify further development.Foghorn and Lilly began working together in 2021 under a deal that included $300 million upfront and an $80 million Lilly equity investment. FHD-909 was the partnership’s first program.<h2 class="st-heading-2">Wedbush Says Bullish Thesis No Longer Applies</h2>Wedbush downgraded Foghorn to ‘Neutral’ from ‘Outperform’ and cut its price target to $2 from $10, according to The Fly. The firm said the Lilly partnership had been a major part of its bullish thesis, which no longer applies.Guggenheim cut its target to $5 from $12 but kept a ‘Buy’ rating, saying Foghorn still has several potential opportunities in its wholly owned pipeline. H.C. Wainwright also maintained ‘Buy’ while lowering its target to $5 from $13, highlighting potential in Foghorn’s EP300 degrader program for blood cancers.Foghorn cut about 40% of its workforce, adding that it would focus on EP300 and CBP degraders, an oral immunology program. The restructuring is expected to extend its cash runway into the second half of 2029.<h2 class="st-heading-2">Retail’s Take On FHTX</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/FHTX">FHTX</a> on Stocktwits flipped to ‘neutral’ from ‘extremely bullish’ over the past 24 hours.The stock has slumped nearly 60% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/fda-flags-evolus-jeuveau-instagram-promotion-as-misleading-seeks-corrective-action/cZDjjKrRBK0">FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Foghorn Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Current Price	$2.10
Prev Close	$2.13
Open	$2.19
Dividend Yield	0.00%
50-Day Moving Average	$3.41
Beta	1.79
Avg. Volume	1.36M
PE Ratio	-2.09

52-Week High	$7.61
52-Week Low	$1.79
Market Capitalization	$126.49M
EPS (Annual)	-$1.18
Price to Book	-1.54
Revenue Per Employee	$291,594.34

Feed

News

Sentiment

Earnings

Fundamentals

Info

FHTX Fundamentals